Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects

Trial Profile

Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Nivolumab (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CheckMate 205
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 29 Nov 2017 According to a Bristol-Myers Squibb media release, data of the trial will be present at the 59th Annual Meeting & Exposition of the American Society of Hematology 2017.
    • 19 Oct 2017 Planned End Date changed from 31 Dec 2018 to 1 Oct 2020.
    • 25 Jun 2017 Results from the extended follow-up presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top